Archive for YK11

What is YK11, how does YK11 work

What is YK11?

(17α,20E)-17,20-[(1-methoxyethylidene)bis-(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11), which the myogenic differentiation of C2C12 myoblast cells is induced by the novel androgen receptor (AR) partial agonist.as well as by dihydrotestosterone (DHT).

YK11 is a selective androgen receptor modulator (SARM), which activates AR without the N/C interaction. In this study, we further investigated the mechanism by which YK11 induces myogenic differentiation of C2C12 cells. The induction of key myogenic regulatory factors (MRFs), such as myogenic differentiation factor (MyoD), myogenic factor 5 (Myf5) and myogenin, was more significant in the presence of YK11 than in the presence of DHT. YK11 treatment of C2C12 cells, but not DHT, induced the expression of follistatin (Fst), and the YK11-mediated myogenic differentiation was reversed by anti-Fst antibody.

Myogenic differentiation is in reference to the products ability to block myostatin. Myostatin inhibition has been a really popular movement since the ban of most prohormones as it looks to be a relatively unexplored area for muscle growth and fat loss. There are currently a lot of claims about mystatin inhibition, but not so much factual data on these products. YK11 will have similar affects to DHT (possibly more potent) without the negatives of DHT. What this means is that the product will most likely be suppressive and require a post cycle, but not cycle support. It also won’t have androgenic side affects like hair loss, acne, etc. The increase in follistatin caused by YK11 will act as an antagonist to mystatin (it will block myostatin) as well as the anabolic growth properties of YK11.

How does YK11 work?

In direct comparison to to LGD-4033 as the reference for assay upon animal models of anabolism and androgenicity, YK-11 demonstrated higher efficacy withing anabolic parameters and lesser androgenicity at equivalent dosages.

It induces muscle cells to make more follistatin which is a strong myostatin inhibitor. Myostatin (also known as growth differentiation factor 8, is a myokine (protein) produced by muscle cells that acts on muscle cells to inhibit myogenesis. Myogenesis is muscle cell growth and differentiation. Research through the years show that when you block myostatin, it allows for significantly more muscle mass. So in research myostatin inhibitors are researched to find cures for muscle diseases.

We expect YK11 to be more potent than SARM LGD in terms of overall growth and feel. At this time, we expect this to be the strongest SARM on the market at a regular dosing. While suppression can occur, we expect this product to have low androgenic properties and can be used by both men and women. From our experience with SARMs, we find there are less losses of on-cycle results than pro-hormones, although typically not as potent. We do expect this product to have similar results as a moderately dosed Halodrol, without the alpha-male/androgenic feelings while on it.

YK11 Dosages and Possible Suggestion

Recommended maximum dose YK11 is require dosages of 2.0-5.0mg b.i.d. in males and 0.5mg-2mg b.i.d. in females to achieve optimal effects in humans for the noted indications

Share with your friendsEmail this to someoneTweet about this on TwitterShare on Google+Share on FacebookPin on PinterestDigg thisShare on StumbleUponShare on TumblrShare on Reddit

YK11- a SARM and myostatin inhibitor

yk11 molecule - sarm

YK11 (also known by its chemical name (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester) is a promising new research compound found to be an agonist of the androgen receptor (AR) leading it to be classified as a SARM. YK11 research has also found it to possess a great ability to inhibit myostatin. These qualities have led to its growing use in muscle wasting/building research. YK11 activates the AR without causing unwanted side effects commonly associated in anabolic/androgenic research of the past. YK11’s ability to inhibit myostatin plays a major role in its muscle and tissue building qualities. YK11 induces “myogenic differentiation of C2C12 cells and the expression of follistatin”. Follistatin plays a vital role in the tissue building and repair of many species and research notes; “increasing the amount of follistatin, resulted in greatly increased muscle mass”. This is clearly an important aspect to the anabolic effects seen in YK11 research and shows it’s a multifaceted compound with a wide array of research opportunities. YK11 is the latest flavor of the month in the underground gray market bodybuilding supplement world. YK11 is a steroidal molecule that has only been shown to have effects in cellular assays. This means that there are no published results in animals or humans as yet. Even so it has popped up for sale on the internet as an anabolic SARM or Selective Androgen Receptor Modulator.

SARMs are molecules that have the anabolic effects of steroids like testosterone or nandrolone but lack a lot of the negative side effects like hair loss, prostate enlargement and acne. New age SARMs like LGD-4033 and Ostarine are non-steroidal, meaning that they do not have the typical four ring structure of classical androgens like testosterone. Steroids like Nandrolone and perhaps trenbolone can be considered to be SARMs since they convert through 5-alpha reduction to less potent androgens and in reasonable doses show more anabolic than androgenic effects. Steroid has been turned into a bad word so for the most part, companies are developing non-steroidal SARMS. In reality, it makes little difference the shape of the molecule but rather what its effects are.

DHT YK11
YK11 Effect on DHT Induced Androgen Receptor Activation

YK11 is steroidal. In fact, it looks a lot like nandrolone. The two papers that are available show that YK11 can activate the androgen receptor but that it does so only partially. This results in an effect known as partial agonism. This means that YK11 can potentially displace stronger androgens while exerting a lower overall stimulating effect on the receptor. In fact the paper by Kanno et al demonstrates this effect by bathing cells in DHT alone or in DHT + YK11. Those cells that received both DHT and YK11 had less androgenic stimulation than with DHT alone. This is important since, in the presence of stronger androgens, YK11 will actually reduce androgen receptor stimulation. In the case of the prostate or hair follicle, this can be a good thing. In skeletal muscle, this will not be a good thing.

Share with your friendsEmail this to someoneTweet about this on TwitterShare on Google+Share on FacebookPin on PinterestDigg thisShare on StumbleUponShare on TumblrShare on Reddit
eXTReMe Tracker